Manipal Health Enterprises Limited vs Sun Pharmaceutical Industries Limited

A side-by-side comparison of Manipal Health Enterprises Limited (MANIPALHOS) and Sun Pharmaceutical Industries Limited (SUNPHARMA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Sun Pharmaceutical Industries Limited leads MANIPALHOS vs SUNPHARMA on 11 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

48.81
P/E ratio
40.66
5.22
P/B ratio
20.07
0.00%
Dividend yield
0.82%
₹13.89
EPS
₹47.84

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

11.80%
Return on equity
16.00%
12.00%
Return on capital
21.00%
27.00%
EBITDA margin
30.00%
17.24%
Net margin
19.69%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

63.48%
Revenue CAGR (3Y)
10.03%
67.79%
Profit CAGR (3Y)
10.57%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹89,104 Cr
Market cap
₹4.68L Cr
₹3,104 Cr
Revenue
₹58,462 Cr
₹535 Cr
Net profit
₹11,509 Cr
1.35
Debt / equity
0.61
Manipal Health Enterprises Limited
  • ["Company has a low return on equity of 10.3% over last 3 years."]
Sun Pharmaceutical Industries Limited
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 34.1%"]
  • ["The company has delivered a poor sales growth of 11.8% over past five years."]
Manipal Health Enterprises Limited full analysis Sun Pharmaceutical Industries Limited full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

MANIPALHOS vs SUNPHARMA: Share Price, Valuation & Which to Buy | DocStoX